Synerkine collaboration partner receives LSH-TKI grant

Dr. Mastbergen from the University Medical Center Utrecht has been awarded a grant for a collaborative effort with Synerkine Pharma to develop a treatment for knee osteoarthritis. The treatment consists of a fusion protein of two cytokines: IL-4 and IL-10. These endogenous proteins have an innate immune-regulatory function and their fusion results in an increased effect compared to the combination of the individual cytokines. Besides the anti-inflammatory activity, data shown that this new molecule has a positive impact on cartilage metabolism and reduces pain. In this collaboration, further investigation in this triple activity will be performed in human cartilage tissue from osteoarthritis patients and animal models of osteoarthritis.